C3AR1 and breast carcinoma: The anti-tumoral effects of the agonist are regulated by the modulation of immune cell functions, as evidenced by the low mRNA expression of C3aR and C5aR1 detected in EMT6 and 4T1 mammary carcinoma cell lines by qPCR analysis.